Search results for "GLP-1 obesity drugs"

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

To Curb GLP-1 Misuse, Experts Urge Tracking Who Gets Prescribed Wegovy and Mounjaro—and Why

As the adoption of GLP-1 receptor agonist obesity medications such as Wegovy and Mounjaro accelerates, medical experts are calling for structured...
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports

GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are increasingly recognized for benefits...
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone

Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone

South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1...
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less

The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less

"First I’ll lose the weight, and then I’ll start exercising." It is a thought shared by almost anyone starting highly...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use

GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use

A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care

The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care

GLP-1 receptor agonists (such as Wegovy and Ozempic), currently dominating the headlines as weight loss medications,...
Daegu’s APAAC 2026 Opens With Expanded Focus on Healthspan Beyond Cosmetic Anti-Aging

Daegu’s APAAC 2026 Opens With Expanded Focus on Healthspan Beyond Cosmetic Anti-Aging

The 9th Asia Pacific Anti-Aging Conference (APAAC 2026), one of Daegu’s flagship international medical events, will run...
Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

Lexraza Developer and Lilly Obesity Chief to Headline Global Clinical Trial Summit in Seoul

What will it take to build on the success of Lexraza, South Korea’s landmark lung cancer drug, and propel it into the...
Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings

A recent observational study indicates that individuals taking popular GLP-1 receptor agonist obesity medications may...
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour

Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...